Ramelteon (TAK-375), A Selective MT1/MT2-Receptor Agonist, Reduces Latency to Persistent Sleep in a Model of Transient Insomnia Related to a Novel Sleep Environment

Abstract

Objective Evaluate the efficacy of ramelteon, an MT/1MT2-receptor agonist, for the treatment of transient insomnia in healthy adults. Design Randomized, double-blind, placebo-controlled design using a model of transient insomnia related to sleeping in a novel environment. Setting Fourteen sleep research centers. Participants Healthy adults (N=375; 228 women), aged 35 to 60 years, who had never previously slept in a sleep laboratory and had a reported usual sleep duration of 6.5 to 8.5 hours and usual bedtime between 8:30 PM and midnight. Interventions Single administration of ramelteon (16 or 64 mg) or placebo 30 minutes before bedtime. Outcome measures Primary efficacy measure was latency to persistent sleep. Also evaluated were total sleep time, wake after sleep onset, percentage of each sleep stage, subjective estimates of sleep from postsleep questionnaire, number of awakenings, and subjective number of awakenings. Residual effects were assessed via Digit Symbol Substitution Test and postsleep questionnaire. Results Participants in ramelteon-treated groups had significantly shorter latency to persistent sleep relative to placebo. They also were associated with significantly longer total sleep time. Wake after sleep onset and time spent in each sleep stage were not significantly different from placebo. The use of ramelteon (16 mg) was associated with a shorter subjective sleep latency compared to placebo. Other subjective measures of sleep did not differ significantly from…